Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
:ALMS
ALMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.76 - $13.11
Previous CloseN/A
Volume29.29K
Average Volume (3M)613.11K
Market Cap
$453.72M
Enterprise Value-$218.00M
Total Cash (Recent Filing)$486.32M
Total Debt (Recent Filing)$38.78M
Price to Earnings (P/E)―
Beta-2.16
Next Earnings
Nov 12, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.77
Shares Outstanding96,879,395
10 Day Avg. Volume484,859
30 Day Avg. Volume613,108
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.48
Enterprise Value/Revenue-9.44
Enterprise Value/Gross Profit-10.50
Enterprise Value/Ebitda0.50
Forecast
1Y Price Target
$19.60Price Target Upside348.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesThe completion of enrollment for the Phase 2b trial of ESK-001 in systemic lupus erythematosus (SLE) is a significant milestone for Alumis.
Market PositionManagement’s emphasis on simplicity, lack of prior authorization hurdles, favorable COGS, and a planned QD formulation option bolster its commercial positioning.
Regulatory PathwayThe potential accelerated regulatory path for ESK-001 in psoriasis, with a filing of 24-week results and subsequent submission of 52-week data, indicates confidence in the product's approval process.
Bears Say
Approval ProbabilityThere is only a 20% probability of approval for ESK-001 in systemic lupus erythematosus (SLE), reflecting uncertainty in the regulatory process.
Development RisksKey risks include the inability to advance ESK-001 into pivotal trials in a timely manner and failure to secure approval in major markets.
Pipeline DelaysPipeline updates include a delay for A-005, now expected to begin a Phase 2 trial in 1H26 vs. 2025 previously.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $13.11 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $453.72M.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 60 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Aug 13, 2025. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.772 by -$0.002.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.92.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 96,879,395 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of $0.77 in its last earnings report, missing expectations of $0.772. Following the earnings report the stock price went down -0.679%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
Alumis Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.60 (348.51% Upside)
$19.60 (348.51% Upside)
Blogger Sentiment
Bearish
ALMS Sentiment 70%
Sector Average 74%
Sector Average 74%
Hedge Fund Trend
Increased
By 287.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.19%
12-Months-Change
Fundamentals
Return on Equity
-66.35%
Trailing 12-Months
Asset Growth
130.38%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$19.60
▲(348.51% Upside)
Technical Analysis
Celcuity
―
Oric Pharmaceuticals
―
Erasca
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
68.89% Insiders
1.39% Mutual Funds
0.01% Other Institutional Investors
23.21% Public Companies and Individual Investors